Search

Your search keyword '"Ranque, S."' showing total 510 results
Start Over Author "Ranque, S."
510 results on '"Ranque, S."'

104. Santé et urbanisation en Afrique

Author

Ranque, S., Chippaux, Jean-Philippe, Garcia, A., and Boussinesq, Michel

Subjects
TRAITEMENT MEDICAL, ENFANT D'AGE SCOLAIRE, PARASITOSE INTESTINALE, IVERMECTINE, ANALYSE DE COHORTES, MEDICAMENT, NEMATODE, INFESTATION, EFFICACITE, PREVALENCE
Published
2003

113. Construction, validation et amélioration continue de banque de spectres pour l’utilisation en routine de la spectrométrie de masse en mycologie médicale

Author

Cassagne, C., primary, Normand, A.-C., additional, Hendrickx, M., additional, Roesems, S., additional, Bourgeois, N., additional, Murat, J.-B., additional, Bouchara, J.-P., additional, Dalle, F., additional, Contet-Audonneau, N., additional, Gari-Toussaint, M., additional, Marinach-Patrice, C., additional, L’Ollivier, C., additional, Ranque, S., additional, and Piarroux, R., additional

Published
2012
Full Text
View/download PDF

115. The efficacy of voriconazole in 24 ocular Fusarium infections

Author

Troke, P., primary, Obenga, G., additional, Gaujoux, T., additional, Goldschmidt, P., additional, Bienvenu, A.-L., additional, Cornet, M., additional, Grenouillet, F., additional, Pons, D., additional, Ranque, S., additional, Sitbon, K., additional, Chaumeil, C., additional, Borderie, V., additional, and Lortholary, O., additional

Published
2012
Full Text
View/download PDF

131. Mise en cohérence et utilisation de différents sous-systèmes d’information hospitaliers pour la surveillance des aspergilloses invasives hospitalières

Author

Gaudart, J., primary, Dufour, J.C., additional, Ranque, S., additional, Giorgi, R., additional, Michel-Nguyen, A., additional, Galambrun, C., additional, Coze, C., additional, Delorme, J., additional, Rasson, S., additional, Lepidi, H., additional, Petit, P., additional, Dumon, H., additional, and Fieschi, M., additional

Published
2008
Full Text
View/download PDF

132. Comparison of MALDI-TOF mass spectra with microsatellite length polymorphisms in Candida albicans.

Author

Dhieb, C., Normand, A. C., L'Ollivier, C., Gautier, M., Vranckx, K., El Euch, D., Chaker, E., Hendrickx, M., Dalle, F., Sadfi, N., Piarroux, R., and Ranque, S.

Subjects
CANDIDA albicans, FUNGAL adaptation, EPIDEMIOLOGICAL research, MATRIX-assisted laser desorption-ionization, MASS spectrometry, MICROBIAL sensitivity tests, GENETIC polymorphisms
Abstract

Candida albicans is the most frequent yeast involved in human infections. Its population structure can be divided into several genetic clades, some of which have been associated with antifungal susceptibility. Therefore, detecting and monitoring fungal clones in a routine laboratory setting would be a major epidemiological advance. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectra results are now widely used as bar codes to identify microorganisms in clinical microbiology laboratories. This study aimed at testing MALDI-TOF mass spectra bar codes to identify clades among a set of C. albicans isolates. Accordingly, 102 clinical strains were genotyped using 10 microsatellite markers and analyzed via MALDI-TOF mass spectrometry. The mass spectra were compared with a reference spectral library including 33 well-characterized collection strains, using a MicroflexTM system and BiotyperTM software, to test the capacity of the spectrum of a given isolate to match with the reference mass spectrum of an isolate from the same genetic clade. Despite high confidence species identification, the spectra failed to significantly match with the corresponding clade ( p = 0.74). This was confirmed with the MALDI-TOF spectra similarity dendrogram, in which the strains were dispersed irrespective of their genetic clade. Various attempts to improve intra-clade spectra recognition were unsuccessful. In conclusion, MALDI-TOF mass spectra bar code analysis failed to reliably recognize genetically related C. albicans isolates. Further studies are warranted to develop alternative MALDI-TOF mass spectra analytical approaches to identify and monitor C. albicans clades in the routine clinical laboratory. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

135. Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of CandidaIsolates to Micafungin

Author

Bougnoux, M.-E., Dannaoui, E., Accoceberry, I., Angoulvant, A., Bailly, E., Botterel, F., Chevrier, S., Chouaki, T., Cornet, M., Dalle, F., Datry, A., Dupuis, A., Fekkar, A., Gangneux, J. P., Guitard, J., Hennequin, C., Le Govic, Y., Le Pape, P., Maubon, D., Ranque, S., Sautour, M., Sendid, B., and Chandenier, J.

Abstract

ABSTRACTIn vitrosusceptibility of 933 Candidaisolates, from 16 French hospitals, to micafungin was determined using the Etest in each center. All isolates were then sent to a single center for determination of MICs by the EUCAST reference method. Overall essential agreement between the two tests was 98.5% at ±2 log2dilutions and 90.2% at ±1 log2dilutions. Categorical agreement was 98.2%. The Etest is a valuable alternative to EUCAST for the routine determination of micafungin MICs in medical mycology laboratories.

Published
2016
Full Text
View/download PDF

140. Isolement d’Exophiala dermatitidis dans des prélèvements d’origine pulmonaire : à propos de six patients.

Author

Michel-Nguyen, A., Favel, A., Dannaoui, E., Duhamel, C., Garcia-Hermoso, D., and Ranque, S.

Subjects
MYCOSES, CYSTIC fibrosis, LUNG infections, ANTIFUNGAL agents
Abstract

Copyright of Journal of Medical Mycology / Journal de Mycologie Médicale is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2009
Full Text
View/download PDF

142. The treatment of prostatitis

Author

Adehossi, E., Ranque, S., and Brouqui, P.

Subjects
*PROSTATITIS, *PELVIC pain
Abstract

Purpose. – Prostatitis are frequently recognized in general practice and often are a diagnosis and therapeutic challenge. We review here the updated knowledge on diagnosis and therapy of prostatitis.Current knowledge and key points. – Prostatitis are divided into acute bacterial prostatitis (I), chronic bacterial prostatitis (II), chronic prostatitis/ chronic pelvic pain syndrome (III) and asymptomatic inflammatory prostatitis. Chronic prostatitis/ chronic pelvic pain syndrome are divided  into : inflammatory (IIIA) and noninflammatory (IIIB). Treatment of prostatitis should follow evidence based guidelines recently published. Acute prostatitis should be treated by ciprofloxacine 500 mg tid or ofloxacine 200 mg bid or cotrimoxazole 960 mg bid for 4 weeks (CIII). When bacteremia occurs third generation cephalosporin with gentamicin  should be used (CIII). In chronic bacterial prostatitis ciprofloxacine 500 mg tid or ofloxacine 200 mg bid or norfloxacine 400 mg bid or cotrimoxazole 960 mg bid for 4 weeks may be used (BIII).Future prospects and projects. – Molecular techniques should improve the etiological diagnosis of prostatitis and their treatment. [Copyright &y& Elsevier]

Published
2002

143. Follow-up of Ascaris lumbricoides and Trichuris trichiura infections in children living in a community treated with ivermectin at 3-monthly intervals.

Author

Ranque, S., Chippaux, J. P., Garcia, A., and Boussinesq, M.

Subjects
*INTESTINAL infections, *IVERMECTIN, *ASCARIS lumbricoides, *INFECTION in children, *DRUG efficacy
Abstract

Ivermectin treatment was administered every 3 months over a 1-year period (April 1993-April 1994) to the whole eligible population of a village in South Cameroon where both Ascaris lumbricoides and Trichuris trichiura were hyper-endemic. A parasitological stool examination was performed before each treatment. Thirty children, aged 5-15 years, were not only found egg-positive for A. lumbricoides and/or T. trichiura before the first treatment but were also each treated and examined in each treatment round. Among these children, the intensity of infection with A. lumbricoides decreased significantly following the first treatment but thereafter remained steady. In contrast, the repeated ivermectin treatments had no significant impact on the intensity of the T. trichiura infections or on the prevalence of infection with T. trichiura or A. lumbricoides among the 30 children. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

144. Evaluation of the AspergillusWestern Blot IgG Kit for Diagnosis of Chronic Aspergillosis

Author

Oliva, A., Flori, P., Hennequin, C., Dubus, J.-C., Reynaud-Gaubert, M., Charpin, D., Vergnon, J. M., Gay, P., Colly, A., Piarroux, R., Pelloux, H., and Ranque, S.

Abstract

ABSTRACTImmunoprecipitin detection (IPD) is the current reference confirmatory technique for anti-Aspergillusantibody detection; however, the lack of standardization is a critical drawback of this assay. In this study, we evaluated the performance of the AspergillusWestern blot (Asp-WB) IgG kit (LDBio Diagnostics, Lyon, France), a recently commercialized immunoblot assay for the diagnosis of various clinical presentations of chronic aspergillosis. Three hundred eight serum samples from 158 patients with aspergillosis sensu lato(s.l.) were analyzed. More specifically, 267 serum samples were derived from patients with Aspergillusdisease, including 89 cases of chronic pulmonary aspergillosis, 10 of aspergilloma, and 32 of allergic bronchopulmonary aspergillosis, while 41 samples were from patients with Aspergilluscolonization, including 15 cystic fibrosis (CF) and 12 non-CF patients. For blood donor controls, the Asp-WB specificity was 94%, while the kit displayed a sensitivity for the aspergillosis s.l. diagnosis of 88.6%, with a diagnostic odds ratio (DOR) of 119 (95% confidence interval [CI], 57 to 251). The DOR values were 185.22 (95% CI,78.79 to 435.45) and 43.74 (95% CI, 15.65 to 122.20) for the diagnosis of Aspergillusdisease and Aspergilluscolonization, respectively. Among the patients, the sensitivities of the Asp-WB in the diagnosis of Aspergilluscolonization were 100% and 41.7% in CF and non-CF patients, respectively. The Asp-WB yielded fewer false-negative results than did IPD. In conclusion, the Asp-WB kit performed well for the diagnosis of various clinical presentations of aspergillosis in nonimmunocompromised patients, with an enhanced standardization and a higher sensitivity than with IPD, which is the current reference method.

Published
2014
Full Text
View/download PDF

145. Platelia Aspergillus assay for diagnosis of disseminated histoplasmosis.

Author

Ranque, S., Pelletier, R., Michel-Nguyen, A., and Dromer, F.

Subjects
*ASPERGILLUS, *MONILIACEAE, *HISTOPLASMOSIS, *RETICULO-endothelial system infections, *ANTIGENS, *DIAGNOSIS, *CLINICAL medicine, *PATIENTS
Abstract

The Platelia Aspergillus assay tested positive in 8 of 11 patients with disseminated histoplasmosis. While other available methods for diagnosis have several drawbacks, this cross-reactivity is particularly valuable in the perspective of practitioners outside the USA who cannot use the test detecting antigen of Histoplasma capsulatum. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

146. Use of MALDI-TOF MS for fungal species distribution of interdigital intertrigo in seafarers, Dakar, Senegal.

Author

Diongue, K., Samb, D., Seck, M.C., Diallo, M.A., Ndiaye, M., Faye, M.D., Badiane, A.S., Ranque, S., and Ndiaye, D.

Abstract

To determine fungal species distribution of interdigital intertrigo among seafarers in Dakar, Senegal, a cross-sectional study was carried out from May to August 2017 among seafarers clinically diagnosed with interdigital intertrigo. A questionnaire was filled to each patient before sampling the affected folds and transporting to Aristide Le Dantec University Hospital where mycological analyses were realized. Species identification by MALDI-TOF MS was performed in Marseille, France. In total, 169 men (21–66 years) were included. Few of them (3%) had a high level of education and the duration of the mycosis exceed 10 years for 88% of patients. Direct microscopic examination (ME) was positive in 34.3%. Among samples with positive ME, 58.6% had positive culture. An overall incidence of 30.2% was found. Patients with confirmed cases aged between 28 and 66 years. Among them, those between 36–50 years were predominant (52.9%). Those with a high level of education were less representative (2%). For 52.1% of patients, the duration of the mycosis was superior to 10 years. Furthermore, 57% of cases were significantly associated with other types of tinea pedis and/or onychomycosis (P = 0.03). Culture was positive in 23.7% isolating 43 strains successfully identified at the species level by MALDI-TOF MS for 31 isolates: 20 Candida and 11 dermatophytes. The rest was identified only at the genus level belonged to Fusarium. In definitive, MALDI-TOF MS could be a useful tool for routine and fast identification of dermatophytes, yeasts and NDFF in clinical mycology laboratories. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

147. Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 AspergillusSection NigriIsolates

Author

Carrara, B., Richards, R., Imbert, S., Morio, F., Sasso, M., Zahr, N., Normand, A. C., Le Pape, P., Lachaud, L., Ranque, S., Maubon, D., Piarroux, R., and Fekkar, A.

Abstract

Aspergillus niger, the third species responsible for invasive aspergillosis, has been considered as a homogeneous species until DNA-based identification uncovered many cryptic species. These species have been recently reclassified into the Aspergillussection Nigri. However, little is yet known among the section Nigriabout the species distribution and the antifungal susceptibility pattern of each cryptic species. A total of 112 clinical isolates collected from 5 teaching hospitals in France and phenotypically identified as A. nigerwere analyzed.

Published
2020
Full Text
View/download PDF

148. [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin]

Author

Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, Schneider D, and Jean-Philippe Chippaux

Subjects
Adult, Male, Ivermectin, Fever, Pruritus, Headache, Middle Aged, Onchocerciasis, Parasitemia, Arthralgia, Loa, Proteinuria, C-Reactive Protein, Filaricides, Loiasis, Animals, Diethylcarbamazine, Humans, Female, Cameroon, Microfilariae, Aged, Hematuria
Abstract

In the last ten years ivermectin appeared an efficient and safe alternative to diethylcarbamazine which is known to induce severe adverse reactions in loiasis, including encephalitis. After these results, large scale ivermectin treatments against onchocerciasis were carried out in Central Africa where loiasis is also endemic; and seven cases of severe reaction were reported in Cameroon since 1991, during these mass ivermectin treatments. In order to study adverse reactions in patients harbouring high load of Loa loa microfilariae (mf), we realized careful hospital based treatment in 112 patients with more than 3,000 mf/ml (ml) blood. Patients received once 200 micrograms ivermectin per kilogram at day 0 (D0). Clinical examination was made daily during the four following days (D1 to D4). Blood and urine samples were analysed before treatment and at D1 and D3. Lumbar puncture was made at D1 for 39 patients with more than 10,000 mf/ml; at D3 for the 49 following patients without consideration for the level of parasitaemia, and at D0 and D3 for ten voluntary patients. For analysis the patients were distributed in 3 groups according to initial parasitaemia: the first group included 50% out of the patients, those whose parasitaemia was fewer than 15,000 mf/ml blood; the second group included 25% patients whose parasitaemia was between 15,000 and 30,000 mf/ml; the third group included the last 25% patients whose parasitaemia was higher than 30,000 mf per ml blood. Adverse reactions were observed in 71% out of the patients. Symptoms described were fever, pruritus, headache, arthralgia. Most symptoms appeared 24 to 36 hours after treatment. Temperature increased significantly in group 3. Microfilaraemia decreased by 85% in the 3 groups during the 4 days following treatment. C-reactive-protein increased dramatically after treatment in all patients (p10(-4)). Some patients presented blood in urine in three groups but haematuria reached 35% of patients in group 3. Proteinuria is noted among 33% of all patients but 20% in group 1 and 2 versus 70% in group 3. Loa loa mf were observed in urine of half the patients, but in low amounts (10 mf per 50 ml urine). In cerebro-spinal fluid (CSF), some mf appeared at D1 or D3 in people heavily infected with Loa loa, reaching 80% of the patients of group 3. LP made at D0 in ten patients with parasitaemia higher than 30,000 mf/ml blood confirmed that CSF was naturally microfilaria free before treatment. One patient presented severe troubles with fever, asthenia and conscience troubles beginning at D3, reactive coma at D4, renal impairment with transitory anuria; progressive improvement in 2 weeks and complete recovery at D22; he presented 102 mf/ml CSF at D6. The study confirmed that ivermectin treatment is generally well tolerated. Among people with high Loa loa parasitaemia the symptoms after treatment are frequent but mild. However severe cases with conscience troubles are possible, and may occur in about 1% of subjects with more than 3,000 mf/ml blood. Severity of adverse reactions was linked to level of parasitaemia before treatment. The critical parasitaemia level which could lead to expect serious adverse effects seems to be 30,000 ml/ml blood. These informations should induce carefulness to carry out large scale treatments against filariosis in endemic areas of Loa loa.

149. Corrigendum: Environmental distribution of Cryptococcus neoformans and C. gattii around the Mediterranean basin [FEMS, (2016), 16, 4] doi: http://dx.doi.org/10.1093/femsyr/fow045

Author

Cogliati, M. D'Amicis, R. Zani, A. Montagna, M.T. Caggiano, G. De Giglio, O. Balbino, S. De Donno, A. Serio, F. Susever, S. Ergin, C. Velegraki, A. Ellabib, M.S. Nardoni, S. Macci, C. Oliveri, S. Trovato, L. Dipineto, L. Rickerts, V. McCormick-Smith, I. Akcaglar, S. Tore, O. Mlinaric-Missoni, E. Bertout, S. Mallié, M. Martins, M.L. Vencà, A.C.F. Vieira, M.L. Sampaio, A.C. Pereira, C. Criseo, G. Romeo, O. Ranque, S. Al-Yasiri, M.H.Y. Kaya, M. Cerikcioglu, N. Marchese, A. Vezzulli, L. Ilkit, M. Desnos-Ollivier, M. Pasquale, V. Korem, M. Polacheck, I. Scopa, A. Meyer, W. Ferreira-Paim, K. Hagen, F. Theelen, B. Boekhout, T. Lockhart, S.R. Tintelnot, K. Tortorano, A.M. Dromer, F. Varma, A. Kwon-Chung, K.J. Inácio, J. Alonso, B. Colom, M.F.

Abstract

The original article published in FEMS Yeast Research Vol. 16. Iss. 4; doi: http://dx.doi.org/10.1093/femsyr/fow045 This paper has been updated to correct a spelling error concerning an author name. It previously showed as Giuseppe Griseo, however the correct spelling is Giuseppe Criseo. © FEMS 2016. All rights reserved.

150. Species Identification and In VitroAntifungal Susceptibility of Aspergillus terreusSpecies Complex Clinical Isolates from a French Multicenter Study

Author

Imbert, S., Normand, A. C., Ranque, S., Costa, J. M., Guitard, J., Accoceberry, I., Bonnal, C., Fekkar, A., Bourgeois, N., Houzé, S., Hennequin, C., Piarroux, R., Dannaoui, E., and Botterel, F.

Abstract

ABSTRACTAspergillussection Terreiis a species complex currently comprised of 14 cryptic species whose prevalence in clinical samples as well as antifungal susceptibility are poorly known. The aims of this study were to investigate A. Terreiclinical isolates at the species level and to perform antifungal susceptibility analyses by reference and commercial methods. Eighty-two clinical A. Terreiisolates were collected from 8 French university hospitals. Molecular identification was performed by sequencing parts of beta-tubulin and calmodulin genes. MICs or minimum effective concentrations (MECs) were determined for 8 antifungal drugs using both EUCAST broth microdilution (BMD) methods and concentration gradient strips (CGS). Among the 79 A. Terreiisolates, A. terreus stricto sensu(n= 61), A. citrinoterreus(n= 13), A. hortai(n= 3), and A. alabamensis(n= 2) were identified. All strains had MICs of ≥1 mg/liter for amphotericin B, except for two isolates (both A. hortai) that had MICs of 0.25 mg/liter. Four A. terreusisolates were resistant to at least one azole drug, including one with pan-azole resistance, yet no mutation in the CYP51Agene was found. All strains had low MECs for the three echinocandins. The essential agreements (EAs) between BMD and CGS were >90%, except for those of amphotericin B (79.7%) and itraconazole (73.4%). Isolates belonging to the A. section Terreiidentified in clinical samples show wider species diversity beyond the known A. terreus sensu stricto. Azole resistance inside the section Terreiis uncommon and is not related to CYP51A mutations here. Finally, CGS is an interesting alternative for routine antifungal susceptibility testing.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results